The mitochondrial NADH shuttle system is a targetable vulnerability for Group 3 medulloblastoma in a hypoxic...

Area of Science:

• Pediatric Oncology
• Cancer Metabolism
• Neuro-oncology

Background:

• Group 3 medulloblastoma is an aggressive pediatric brain tumor with poor survival rates.
• Current treatments are inadequate due to a lack of understanding of Group 3 tumor cell molecular features.
• Metabolic adaptations in low oxygen environments are critical for Group 3 tumor progression.

Purpose of the Study:

• To investigate the metabolic vulnerabilities of Group 3 medulloblastoma cells in a hypoxic microenvironment.
• To identify novel therapeutic targets by exploring the role of NADH production pathways.
• To evaluate the efficacy of targeting specific metabolic enzymes and transporters in Group 3 medulloblastoma.

Main Methods:

• Analysis of NADH production using mitochondrial glycerol-3 phosphate (G3PS) and malate-aspartate shuttles (MAS).
• Treatment of Group 3 cells with small molecules targeting G3PS and MAS, Phenformin (mitochondrial complex 1 inhibitor), and lactate dehydrogenase A (LDHA) inhibitors.
• Assessment of cell proliferation, apoptosis, and respiration under varying oxygen concentrations.
• Validation in a 3D human cerebellar organoid model.

Main Results:

• Group 3 cells utilize both G3PS and MAS for NADH production.
• Small molecules targeting G3PS and MAS significantly reduced proliferation and induced apoptosis in Group 3 cells.
• Phenformin and LDHA inhibition enhanced cell death, particularly in hypoxic conditions.
• NADH shuttle inhibitors induced apoptosis in Group 3 human cerebellar organoids.

Conclusions:

• Metabolic heterogeneity exists in medulloblastoma, influenced by oxygen levels.
• Targeting NADH production pathways (G3PS, MAS) presents a promising therapeutic strategy for Group 3 medulloblastoma.
• Combination therapies involving metabolic inhibitors may overcome treatment resistance in aggressive pediatric brain tumors.